NCT01782443View on ClinicalTrials.gov

Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors

PHASE2CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

February 13, 2013

Primary Completion Date

March 31, 2021

Study Completion Date

December 26, 2021

Conditions
Carcinoid Tumor
Interventions
DRUG

Ziv-aflibercept

Trial Locations (3)

02115

Massachusetts General Hospital, Boston

02215

Brigham and Women's Hospital, Boston

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
lead

Dana-Farber Cancer Institute

OTHER

NCT01782443 - Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors | Biotech Hunter | Biotech Hunter